The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
Introduction: As example, M184V/I, the most prevalent NRTI-mutations selected under 3TC or FTC in the reverse transcriptase, do for instance revert partially the effect of thymidine-analogue mutation- (TAM) on resistance.
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
PMID: 21345162
2011
AIDS research and human retroviruses
Abstract: Of 41 children without virologic suppression with posttreatment HIV genotype data available, major resistance mutations were found in 32 (78%): 14 (36%) had PI mutations including V82A, M46I, and L90M; 29 (71%) had M184V/I; and three had NNRTI mutations (K103N, Y181C, and G190A).
Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.
PMID: 21350368
2011
Journal of acquired immune deficiency syndromes (1999)
Abstract: Mutations in the polymerase but not in connection or RNase H domains of RT increased in frequency between pretherapy and failure (K103N, P = 0.001; M184I/V, P = 0.016).
Result: Only K103N and M184I/V were significantly more frequent at failure than pre-therapy (unadjusted p=0.001 and p=0.016, respectively).
Discussion: The only mutations that were significantly more frequent at virologic failure than pre-therapy were K103N (p=0.001) and M184I/V (p=0.016) in the polymerase domain, which confer resistance to the study drugs EFV and 3TC, respectively.
Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
Abstract: Several large-scale HIV-1 genotypic analyses have revealed that the most prevalent nucleos(t)ide analog RT inhibitor (NRTI)-resistance mutation is M184V/I followed by a series of thymidine analog-associated mutations: M41L, D67N, K70R, L210W, T215Y/F and K219Q/E.
Differential persistence of transmitted HIV-1 drug resistance mutation classes.
PMID: 21451005
2011
The Journal of infectious diseases
Abstract: CONCLUSIONS: The rapid replacement of M184V/I mutations is consistent with known fitness costs.
Abstract: RESULTS: Among 75 individuals with 195 TDR mutations, M184V/I became undetectable markedly faster than did nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations (hazard ratio, 77.5; 95% confidence interval [CI], 14.7-408.2; P<.0001), while protease inhibitor and NNRTI replacement rates were similar.
HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis.
Result: Of the 16 infants with HIV drug resistance mutations at 6 mo, 13 (81%) had at least one NRTI resistance mutation (M184 I/V [n = 12], K65R [n = 2], and D67G [n = 1]), and six (38%) had NNRTI resistance mutations (K103N [n = 2], Y181 [n = 2], and G190A [n = 2]) (sequences submitted to GenBank, http://www.ncbi.nlm.nih.gov/Genbank/index.html, accession numbers HM164112-HM164123, HM164127-HM164128, and HM164130-HM164131) (Table 3).
Table: M184I/V
Table: M184I
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
Abstract: Among VF subjects at week 48, 5/26 (19.2%) FTC-treated subjects and 27/77 (35.5%) 3TC-treated subjects developed the M184V/I mutation (P = .145).
Abstract: CONCLUSIONS: The results of this pooled analysis of 3 clinical trials indicate a lower frequency of development of the M184V/I mutation in subjects treated with FTC versus 3TC when combined in regimens containing dual NRTIs and EFV.
Abstract: Multivariate analyses adjusting for baseline viral load, baseline CD4 cell counts, and baseline NRTI resistance showed that treatment with FTC had a significantly lower rate of M184V/I development than treatment with 3TC (odds ratio 0.32; P = .02).
Abstract: PURPOSE: To compare the development of the M184V/I substitution among antiretrov
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.
Result: The Q151M MDR mutations were also genetically linked to NRTI mutations M184IV and L210F, and NNRTI mutations E138A, Y181I and H221Y (Table 1).
Result: The effect on susceptibility to 3TC was probably due to M184I/V mutations which were seen by 4 months.
Result: The patient-derived RT at 4 months had already developed the M184I mutation which is known to affect viral replicative fitness.
High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo.
PMID: 21663632
2011
Journal of the International AIDS Society
Table: M184I
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.
PMID: 21694608
2011
Journal of acquired immune deficiency syndromes (1999)
Abstract: nonnucleoside reverse transcriptase inhibitor-DRM were found in 17 of 36 (47.2%) efavirenz recipients, and M184V/I mutation in 14 of 40 (35.0%) lamivudine recipients.
HIV mutation literature information.
PMID: 
2011
AIDS research and therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT